newsfilter
← Latest News
GlobeNewswire·

Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026

New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatmentUpdated data to be presented from first-in-human trial of LB2501, an investigational,